STOCK TITAN

XBiotech Inc - XBIT STOCK NEWS

Welcome to our dedicated news page for XBiotech (Ticker: XBIT), a resource for investors and traders seeking the latest updates and insights on XBiotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect XBiotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of XBiotech's position in the market.

Rhea-AI Summary
XBiotech Inc. (XBIT) plans to expand its campus headquarters with a new state-of-the-art research and development facility in Austin, Texas. The company has received approval to begin excavation for site preparation, with groundwork expected to start in the 1st quarter of 2024. The new facility will support commercialization plans for the company’s Natrunix rheumatology program and will include clinical and medical operations, commercialization teams, and wet laboratories for ongoing infectious disease programs. The construction will also feature a subterranean parking garage to minimize ecological impact. President and CEO John Simard expressed excitement about the project, highlighting its potential to enhance operational capability and create a leading biotechnology facility in Texas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
none
-
Rhea-AI Summary
XBiotech (NASDAQ: XBIT) Announces Alan Kivitz M.D. as Lead Investigator for Natrunix Clinical Research Program in Rheumatoid Arthritis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.05%
Tags
none
-
Rhea-AI Summary
XBiotech Inc. is developing Hutrukin as a breakthrough therapy to reduce brain injury after stroke. The Phase I study aims to evaluate safety and pharmacokinetics of Hutrukin in healthy volunteers. Hutrukin may reduce inflammatory injuries associated with reperfusion, providing a unique and major advance for stroke victims.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
Rhea-AI Summary
XBiotech completes enrollment of Phase II portion of 1-BETTER study for Natrunix in combination with chemotherapy for treating pancreatic cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.3%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.83%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.02%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.37%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
XBiotech Inc

Nasdaq:XBIT

XBIT Rankings

XBIT Stock Data

281.67M
17.09M
36.02%
11.48%
1.99%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Austin

About XBIT

xbiotech is developing a first-in-class monoclonal antibody (mabp1) to inhibit chronic inflammation. chronic (sterile) inflammatory responses are involved in the progression of many serious and common diseases. mabp1 is being investigated in many important areas of medicine, including: cancer, leukemia (phase 1); type 2 diabetes (phase2); psoriasis (phase 2); and vascular disease (phase 2). mabp1 is a true human™ antibody cloned from a natural human immune response and—unlike currently marketed antibodies—it has not undergone any modification to alter its function. it has exhibited the best potential tolerability and safety during the clinical trials. xbiotech has established a current good manufacturing practices (cgmp) program to commercialize its lead product candidate. the company has purchased land and designed a commercial-scale plant with 25,000l total bioreactor capacity. construction of the facility is planned to commence in 4th quarter 2011..